Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNITUDE-2: NTLA-2001 in ATTRv-PN
NCT06672237Phase 3Active, not recruiting
- Sponsor
- Intellia Therapeutics
- Start
- Nov 2024
- Primary completion
- Jul 2027
- Modality
- Gene Editing, Gene Silencing, Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of nexiguran ziclumeran in hereditary transthyretin amyloidosis polyneuropathy (ATTR-PN) (2 arms), sponsored by Intellia Therapeutics. Primary endpoints: Modified Neuropathy Impairment Score +7 at 18 months and Serum Transthyretin at 29 days. Started Nov 2024; status: active, not recruiting.
02
Drugs
nexiguran ziclumeran
03
Conditions
hereditary transthyretin amyloidosis polyneuropathy (ATTR-PN)
Beyond the preview
Go deeper on NCT06672237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672237.